NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
Clinical Trials
480 trialsNCT04328662 2026-03-04
A Study of Ninlaro in Real World Clinical Practice in China
Takeda
Completed
NCT05561751 2026-02-12
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
GPCR Therapeutics, Inc.
Phase 2 Completed
NCT05014412 2026-02-10
MagnetisMM-9
Pfizer
Phase 2 Completed
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT04674813 2026-02-09
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT03275103 2026-02-05
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Completed
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
NCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT01592370 2025-10-22
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT04773522 2025-10-01
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT04000282 2025-09-12
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Sanofi
Phase 1 Completed
NCT04045795 2025-09-12
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Sanofi
Phase 1 Completed
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT03525678 2025-09-03
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT04772989 2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT03934684 2025-08-06
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT07102706 2025-08-05
Phase I Trial of GR1803 Injection in Patients With RRMM
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT01711671 2025-08-03
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Leap Therapeutics, Inc.
Phase 1 Completed
NCT06163040 2025-07-31
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT03548207 2025-07-30
CARTITUDE-1
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT05011097 2025-07-20
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma Co., Ltd.
Phase 1 Completed
NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed
NCT04083534 2025-05-30
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Phase 1/2 Completed
NCT02519452 2025-05-23
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03361748 2025-05-23
KarMMa
Celgene
Phase 2 Completed
NCT06592222 2025-05-20
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Completed
NCT04176380 2025-05-15
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC
Phase 2 Completed
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03277105 2025-04-29
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT02316106 2025-04-27
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT05347485 2025-04-25
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Janssen Scientific Affairs, LLC
Phase 2 Completed
NCT05673967 2025-04-25
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Completed
NCT03860038 2025-04-24
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd.
Phase 2 Completed
NCT00511082 2025-04-16
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Otsuka Beijing Research Institute
Phase 1 Completed
NCT03288974 2025-04-15
Pomalyst PMS
Celgene
Completed
NCT04758767 2025-04-03
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
CASI Pharmaceuticals, Inc.
Phase 1 Completed
NCT04035226 2025-03-30
LocoMMotion
Janssen-Cilag Ltd.
Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed